Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN; KW-6002 US-001 Study Group.
Kase H, et al. Among authors: kurokawa m.
Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100. doi: 10.1212/01.wnl.0000095219.22086.31.
Neurology. 2003.
PMID: 14663020
Review.